Frank David 11/30/22 Frank David 11/30/22

Red flags in biotech press releases

Learn the classic signs of spin and misdirection in biotech PR about clinical trial results.

Frank David 2/15/22 Frank David 2/15/22

How risky is that biotech trial?

A framework to more methodically assess clinical development probability of success (POS).

Frank David 3/14/21 Frank David 3/14/21

Learn to analyze biotech trials like a pro!

Frank David 2/28/20 Frank David 2/28/20

Our data shed light on disparities in clinical study access across U.S. urban areas.

Frank David 2/2/20 Frank David 2/2/20

How can we balance innovation and affordability in prescription drugs? Peter Kolchinsky has some ideas.

Frank David 5/1/19 Frank David 5/1/19

R&D portfolio strategy is so … unstrategic. Together with Navigant’s Greg Belogolovsky, we have some ideas to fix it.

Frank David 2/28/19 Frank David 2/28/19

As Jay-Z might say, breakthrough status may provide 99 benefits, but excess stock returns ain’t one.

Frank David 9/17/18 Frank David 9/17/18

In his new book, Cass Sunstein explores how to bring analytic rigor to policy decisions.

Frank David 1/28/18 Frank David 1/28/18

Drug price scandals aren’t all the same - but here’s one that may be preventable.